aBLA Filing Intelligence & Biosimilar Opportunity

Winrevair

Sotatercept-Csrk

Antihypertensive

Subcutaneous Injection

Winrevair is used to treat adults with pulmonary arterial hypertension (PAH). It helps improve exercise ability, daily functioning, and lowers the risk of the condition getting worse.

Approval Date

26-Mar-24

Data Exclusivity Expiry

26-Mar-28

Market Exclusivity Expiry

26-Mar-36

Commercial snapshot

Market performance & projections

Revenue ($M)

1443

CAGR (%)

0.416

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2768

2027

3859

2028

4851

2029

5802

2030

6623

2031

7421

2032

8196

Molecule profile

Details & specifications

Molecule

Sotatercept-Csrk

Innovator

MERCK & CO., INC. (MSD)

Dosage Form

Subcutaneous Injection

Strength

45 mg lyophilized cake or powder, 60 mg lyophilized cake or powder

Therapeutic Category

Antihypertensive

Usage

To treat pulmonary arterial hypertension

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.